The use of enoxaparin during percutaneous coronary angioplasty in patients with stable angina

Kardiologia Polska

Volumn 55, Issue 12, 2001, Pages 520-524

  Drozd, Jakub ^a   Opalińska, Edyta ^a   Wójcik, Jaroslaw ^a   Madejczyk, Andrzej ^a  

^a Medical University of Lublin Katedra i Klinika Kardiologii   (Poland)

Author keywords

Enoxaparin; PTCA

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARINUM; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE;

ADULT; AGED; ANGINA PECTORIS; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SUDDEN DEATH; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0035684022     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. The early phenomena of restenosis following percutaneous transluminal coronary angioplasty
2. The HELVETICA investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
3. Relationship between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty
4. The relationship of anticoagulation level and complication after successful percutaneous transluminal coronary angioplasty
5. Adequate heparinization during PTCA: Assessment using activated clotting times
6. Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo
7. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris
8. Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions
9. NICE-3. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI
10. NICE-1. National Investigator Collaboration on Enoxaparin
11. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin
12. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction. TIMI 9b Trial
13. Safety of low dose heparin in elective coronary angioplasty
14. Minimal heparinization in coronary angioplasty. How much heparin is really warranted?
15. A comparison of low-molecular-weight heparin with unfracfionated heparin for unstable coronary artery disease
16. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis IIn Myocardial Infarction (TIMI) 11B trial
17. POLONIA. Polish-American Local Levonox NIR Assessment Study
18. Heparin after percutaneous interventions: The HAPI Trial
19. NICE-4. Enoxaparin-Abciximab for PTCA. The Manual of Interventional Trials. TCT 2000